[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611878":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":23,"centralContacts":24,"locations":30,"responsibleParty":46,"collaborators":48,"id":51,"slug":23,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":23,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":23,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":70,"overallStatus":33,"whyStopped":23,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"TCRCure Biopharma Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"TC-D101 CAR-T Cell Therapy","EXPERIMENTAL","Following lymphodepletion chemotherapy, participants will receive Following lymphodepletion chemotherapy, participants will receive TC-D101 CAR-T Cell CAR-T",[13],"Biological: TC-D101 CAR-T",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","TC-D101 CAR-T","TC-D101 CAR-T treatment follows a lymphodepletion Drug: Fludarabine and Cyclophosphamide.",[9],[21,22],"Fludarabine","Cyclophosphamide",null,[25],{"name":26,"role":27,"phone":28,"phoneExt":23,"email":29},"Tangfeng LV","CONTACT","+862580863234","njzyjg80863256@163.com",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":23,"country":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"The Jinling Hospital","RECRUITING","Nanjing","Jiangsu","China",{"type":38,"coordinates":39},"Point",[40,41],118.77778,32.06167,{"lat":41,"lon":40},[44],{"name":45,"role":27,"phone":28,"phoneExt":23,"email":29},"Tangfeng Hospital",{"type":47,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR",[49],{"name":32,"class":50},"UNKNOWN","100611878",false,"NCT07246304","TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC","A Preliminary Exploratory Clinical Study of TC-D101 in the Treatment of DLL3-Positive Relapsed\u002FRefractory Primary Small Cell Lung Cancer","Inclusion Criteria:\n\n1. Participants must voluntarily provide written informed consent.\n2. Aged 18-75 years (inclusive).\n3. Life expectancy ≥ 3 months.\n4. ECOG performance status 0-1.\n5. Failed or unsuitable for standard therapy.\n6. At least one measurable lesion per RECIST 1.1.\n7. DLL3-positive r\u002Fr SCLC confirmed by immunohistochemistry.\n8. Adequate organ and bone marrow function.\n9. Effective contraception required for participants of childbearing potential.\n10. Adequate venous access for leukapheresis.\n\nExclusion Criteria:\n\n1. Primary CNS malignancy or uncontrolled CNS metastases.\n2. Other malignancies within 5 years (except adequately treated non-melanoma skin cancer or carcinoma in situ).\n3. Active autoimmune disease or history of autoimmune disease.\n4. Immunodeficiency, including HIV positivity.\n5. Bleeding disorders (inherited or acquired).\n6. Clinically significant cardiovascular disease.\n7. Active infection (including tuberculosis, hepatitis B\u002FC, syphilis).\n8. Pregnant or breastfeeding women.\n9. Clinically significant ascites . 10 Uncontrolled pleural effusion or pericardial effusion.\n\n11\\. Prior cell or gene therapy. 12. Severe drug hypersensitivity history. 13. Investigator-assessed unsuitability for trial participation.","ALL","18 Years","75 Years",{"count":61,"type":62},24,"ESTIMATED","INTERVENTIONAL",[65],"EARLY_PHASE1","This is a single-arm, open-label, dose-escalation clinical trial designed to evaluate the safety, tolerability, expansion, and persistence of TC-D101 CAR-T cells in patients with DLL3-positive Relapsed\u002FRefractory primary small cell lung cancer(r\u002Fr SCLC) who have progressed after prior therapies. The primary objective is to determine the maximum tolerated dose (MTD), with a secondary aim to assess preliminary clinical efficacy in SCLC.",[68,69],"Small Cell Lung Cancer ( SCLC )","CAR-T Cell Therapy",[68,69,71],"DLL3","2025-11-17",{"date":74,"type":75},"2025-11-24","ACTUAL",{"date":77,"type":62},"2025-11-30",{"date":79,"type":62},"2028-11-30",{"name":5,"class":6},1]